
Person deep dive
Christoph Lengauer
#77 2026 Strebulaev–Jackson Venture Ranking, emerging firms
Christoph Lengauer is a cancer biologist and a founder and chief scientific officer of Curie.Bio, a Boston seed and Series A biotech firm. As a partner at Third Rock Ventures he co-founded Thrive Earlier Detection, bought by Exact Sciences, and Celsius Therapeutics, bought by AbbVie.
- Founded
- Curie.Bio, Moma Therapeutics, Thrive Earlier Detection +1 more
- Education
- Johns Hopkins University, University of Heidelberg, Paris Lodron University of Salzburg
Track record
Investments Christoph Lengauer is best known for, with what became of them.
- TThrive Earlier DetectionCo-founderAcquired by Exact Sciences in a deal announced in October 2020
- CCelsius TherapeuticsCo-founder and chief scientific officerAcquired by AbbVie
Curie.Bio
FirmCurie.Bio
Founded2022
Based inBoston
Funds$1B under management for seed and Series A rounds (company LinkedIn page)
FocusSeed and Series A drug discovery companies, including spinouts
Career
- 1994Joined Bert Vogelstein's lab at Johns Hopkins, where he later became an associate professor.
- 2006Left Johns Hopkins for Novartis, where he ran an oncology drug discovery unit.
- Became global head of oncology drug discovery and preclinical development at Sanofi.
- Served as chief scientific officer of Blueprint Medicines.
- Joined Third Rock Ventures as a partner and co-founded Thrive Earlier Detection, Celsius Therapeutics and Moma Therapeutics.
- 2020Exact Sciences agreed to buy Thrive and Base Genomics for a combined $2.56B.
- 2022Co-founded Curie.Bio in Boston and became its chief scientific officer.
Sources: Dealroom — Christoph Lengauer · Dealroom — Curie.Bio · Wikipedia — Exact Sciences (Thrive acquisition) · Curie.Bio — Our team. Rank: 2026 Strebulaev–Jackson Venture Ranking.
Companies founded
Currently
Active roles, board seats and partnerships.

raceforlife.org

Johns Hopkins University
Work history
Past roles by Dealroom records.

MKT4INTEL

Third Rock Ventures
→

Blueprint Medicines
$9.1B valuation (2025)Unicorn
→

Sanofi Aventis

Novartis
$303B valuation (2026)
→

Novartis Institutes
Education

Johns Hopkins University

University of Heidelberg

Paris Lodron University of Salzburg



